Allena Pharmaceuticals (ALNA) – Company Press Releases
-
Allena Pharmaceuticals Announces Completion of Enrollment of Cohorts A and B of ALLN-346 Phase 2a Study 202 in Patients with Gout and Stages 2 and 3 Chronic Kidney Disease
-
Allena Pharmaceuticals Announces Completion of Enrollment of Cohorts A and B of ALLN-346 Phase 2a Study 202 in Patients with Gout and Stages 2 and 3 Chronic Kidney Disease
-
Allena Pharmaceuticals Announces New Meeting Date and New Record Date for Special Meeting to Approve Reverse Stock Split
-
Allena Pharmaceuticals Announces New Meeting Date and New Record Date for Special Meeting to Approve Reverse Stock Split
-
Allena Pharmaceuticals Announces Rescheduling of Special Meeting to Approve Reverse Stock Split
-
Allena Pharmaceuticals Announces Rescheduling of Special Meeting to Approve Reverse Stock Split
-
Allena Pharmaceuticals Announces $2.8 Million Registered Direct Offering
-
Allena Pharmaceuticals Announces $2.8 Million Registered Direct Offering
-
Allena Pharmaceuticals Provides Clinical and Corporate Update
-
Allena Pharmaceuticals Provides Clinical and Corporate Update
-
Versantis Appoints Mark Fitzpatrick, Seasoned Biotech Executive, as its New CEO
-
Allena Pharmaceuticals to Participate in the Stifel 2021 Virtual Healthcare Conference
-
Allena Pharmaceuticals to Participate in the Stifel 2021 Virtual Healthcare Conference
-
Allena Pharmaceuticals Reports Third Quarter 2021 Financial Results and Recent Corporate Progress
-
Allena Pharmaceuticals Reports Third Quarter 2021 Financial Results and Recent Corporate Progress
-
Allena Pharmaceuticals Receives Fast Track Designation from FDA for the Development of ALLN-346 for Chronic Treatment of Hyperuricemia in Patients With Gout and Advanced Chronic Kidney Disease
-
Allena Pharmaceuticals Receives Fast Track Designation from FDA for the Development of ALLN-346 for Chronic Treatment of Hyperuricemia in Patients With Gout and Advanced Chronic Kidney Disease
-
Allena Pharmaceuticals Commences Dosing of Gout Patients in Second Phase 2a Trial of ALLN-346
-
Allena Pharmaceuticals Commences Dosing of Gout Patients in Second Phase 2a Trial of ALLN-346
-
Allena Pharmaceuticals to Participate in H.C. Wainwright’s 23rd Annual Global Investment Conference
-
Allena Pharmaceuticals to Participate in H.C. Wainwright’s 23rd Annual Global Investment Conference
-
Allena Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Corporate Progress
-
Allena Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Corporate Progress
-
Allena Pharmaceuticals to Participate in the 12th Annual Wedbush PacGrow Healthcare Conference
-
Allena Pharmaceuticals to Participate in the 12th Annual Wedbush PacGrow Healthcare Conference
-
Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Allena Pharmaceuticals Announces $28 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
-
Allena Pharmaceuticals Announces $28 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
-
Allena Pharmaceuticals Provides Update on Clinical Development Programs
-
Allena Pharmaceuticals Provides Update on Clinical Development Programs
-
Allena Pharmaceuticals, Inc. to Present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference
-
Allena Pharmaceuticals, Inc. to Present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference
-
Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Allena Pharmaceuticals to Host Key Opinion Leader Webinar Focused on ALLN-346 for the Treatment of Gout in Patients with Chronic Kidney Disease
-
Allena Pharmaceuticals to Host Key Opinion Leader Webinar Focused on ALLN-346 for the Treatment of Gout in Patients with Chronic Kidney Disease
-
Allena Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update
-
Allena Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update
-
Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Allena Pharmaceuticals Appoints Mark J. Fitzpatrick to its Board of Directors
-
Allena Pharmaceuticals Appoints Mark J. Fitzpatrick to its Board of Directors
-
Allena Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
-
Allena Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
-
Allena Pharmaceuticals to Present at Upcoming Investor Conferences in March
Back to ALNA Stock Lookup
